Overview

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Status:
Completed

Trial end date:
2020-11-09

Target enrollment:

Participant gender:

Summary

The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Epoetin Alfa
Prolyl-Hydroxylase Inhibitors